LDZA.STU ASPEN PHARMACARE (LDZA.SG)
- Market cap
- -
- P/E
- -
- P/B
- 0.84x
- ROE
- 3.3%
- Dividend yield
- 1.48%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is LDZA.STU undervalued?
Graham numberThe Graham number of ASPEN PHARMACARE (LDZA.SG) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ASPEN PHARMACARE (LDZA.SG) fundamental analysis
No fundamental analysis for ASPEN PHARMACARE (LDZA.SG) yet.
ASPEN PHARMACARE (LDZA.SG) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ASPEN PHARMACARE (LDZA.SG)
There is no Profile data available for LDZA.SG.
Full company profileASPEN PHARMACARE (LDZA.SG) financial statements
ASPEN PHARMACARE (LDZA.SG) annual financial statements (ZAR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 41.2B | 42.6B | 38.9B | 38.6B | 37.8B | 38.6B | 40.7B | 44.7B | 35.3B | 34.9B |
| Gross Profit | 19.9B | 21.6B | 19.7B | 19.3B | 17.8B | 18.3B | 18.4B | 19.5B | 14.8B | 14.1B |
| Operating Income | 8.30B | 10.6B | 9.37B | 8.96B | 8.13B | 8.79B | 8.25B | 10.4B | 4.99B | 4.63B |
| EBITDA | 9.70B | 11.1B | 6.38B | 8.78B | 8.85B | 10.6B | 9.67B | 9.91B | 1.37B | 3.29B |
| Net Income | 5.10B | 6.01B | 6.46B | 4.66B | 4.81B | 6.49B | 5.23B | 4.40B | -1.08B | 2.65B |
| EPS | 11 | 13 | 14 | 10 | 11 | 15 | 12 | 9.91 | -2.44 | 5.99 |
| Balance Sheet | ||||||||||
| Total Assets | 116B | 133B | 122B | 133B | 110B | 111B | 134B | 139B | 136B | 108B |
| Total Liabilities | 73.2B | 82.7B | 68.1B | 64.0B | 44.1B | 40.4B | 48.0B | 54.2B | 51.0B | 27.9B |
| Shareholders' Equity | 43.1B | 50.1B | 54.2B | 69.2B | 65.6B | 70.9B | 86.2B | 84.9B | 84.9B | 80.4B |
| Cash & Short-term Investments | 10.7B | 11.2B | 8.98B | 7.09B | 8.55B | 6.18B | 10.9B | 12.3B | 6.41B | 16.0B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 6.50B | 7.02B | 6.00B | 8.26B | 6.83B | 5.37B | 5.52B | 6.23B | 5.16B | 6.87B |
| Capital Expenditure | 2.60B | 8.23B | 3.58B | 2.69B | 3.43B | 2.70B | 3.18B | 5.54B | 5.06B | 3.04B |
| Free Cash Flow | 3.90B | -1.21B | 2.42B | 5.57B | 3.39B | 2.68B | 2.34B | 690M | 104M | 3.83B |
| Ratios | ||||||||||
| ROE | 11.8% | 12.0% | 11.9% | 6.7% | 7.3% | 9.1% | 6.1% | 5.2% | -1.3% | 3.3% |
| ROA | 4.4% | 4.5% | 5.3% | 3.5% | 4.4% | 5.8% | 3.9% | 3.2% | -0.8% | 2.4% |
| Net Profit Margin | 12.4% | 14.1% | 16.6% | 12.1% | 12.7% | 16.8% | 12.8% | 9.9% | -3.1% | 7.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ASPEN PHARMACARE (LDZA.SG) dividends
- Dividend yield
- 1.48%
- Forward dividend
- -
- Payout ratio
- 35.5%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | ZAR 941M | 2.13 | 35.5% |
| 2025 | ZAR 1.60B | 3.61 | - |
| 2024 | ZAR 1.53B | 3.43 | 34.6% |
| 2023 | ZAR 1.46B | 3.28 | 27.8% |
| 2022 | ZAR 1.20B | 2.69 | 18.4% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | ZAR 1.44B | 3.15 | 22.2% |
| 2018 | ZAR 1.31B | 2.88 | 21.8% |
| 2017 | ZAR 1.20B | 2.63 | 23.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:3 on Apr 19, 2016.
Who owns ASPEN PHARMACARE (LDZA.SG)
Ownership data of ASPEN PHARMACARE (LDZA.SG) is not available yet.
ASPEN PHARMACARE (LDZA.SG) company profile
- Company name
- ASPEN PHARMACARE (LDZA.SG)
- Ticker
- LDZA.STU
- ISIN
- ZAE000066692
- Exchange
- Stuttgart Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- June
- Address
- Website
- -
About ASPEN PHARMACARE (LDZA.SG)
There is no Profile data available for LDZA.SG.